BUZZ-Indivior tumbles on falling sales forecast

Shares of drugmaker Indivior INDV.L down 22.2% at 675 p, lowest since October 24

London-listed co expects 2025 net revenue to decline 17% at midpoint between $955 million and $1,025 million

Co expects more than 50% fall in sales rev for Suboxone Film due to intensified generic pricing activity and potential fifth generic entrant

Co sees net revenue for key drug, SUBLOCADE, largely unchanged, at midpoint between $725m to $765m

INDV expects adjusted operating profit between $185 million to $225 million in 2025

In 2024, shares fell by 13.6%